You are here

Article Text

Article menu
Download PDFPDF
Electronic pages
Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases
  1. F Andersohn1,
  2. F G Hagmann2,
  3. E Garbe1
  1. 1Institute of Clinical Pharmacology, Charité-University Medicine, Berlin, Germany
  2. 2Department of Internal Medicine I, Westpfalz-Klinikum, Kaiserslautern, Germany
  1. Correspondence to:
    Dr med F Andersohn
    Institute of Clinical Pharmacology, Charité-University Medicine Berlin, Campus Charité Mitte, Schumannstrasse 20/21, 10117 Berlin, Germany; frank.andersohncharite.de

Abstract

Clopidogrel has been reported to be safe and effective in reducing vascular events. Nevertheless, there is growing evidence that clopidogrel may cause thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome (TTP/HUS). This association has been debated, since in several cases alternative causes could not be excluded. Two new cases of TTP/HUS associated with clopidogrel are reported here. After discontinuation of clopidogrel and treatment with plasma exchange, both patients had a complete and sustained recovery from TTP/HUS. These cases corroborate previous observations that clopidogrel may indeed be a rare cause of TTP/HUS.

  • CAPRIE, clopidogrel versus aspirin in patients at risk of ischaemic events
  • HUS, haemolytic uraemic syndrome
  • TTP, thrombotic thrombocytopenic purpura
  • platelet aggregation inhibitors
  • clopidogrel
  • thrombotic thrombocytopenic purpura
  • haemolytic uraemic syndrome
  • adverse effects

https://doi.org/10.1136/hrt.2004.039214

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    Linked Articles